DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Hall Venture Partners is located at a state-of-the-art Hall Labs innovation campus in Provo, Utah. Hall Venture Partners was established to address the growing...
Maraia Tanner is the CEO of Star Harbor based in Lone Tree, Colorado. She shares insights into the mission of the organization and how...
Mark Cherney is the Founder and Executive Chairman of both US Urology Partners and Prologics. This past year Mark transitioned from the CEO role...
